IL2 and squamous cell carcinoma: Previously, we used our model system to generate an ADCC-resistant variant of the EGFR-overexpressing squamous cell carcinoma cell-line A431 by continuously challenging cells with three day cycles consisting of the addition of fresh IL-2 stimulated NK92-CD16V cells at a 1:1 effector: target ratio and cetuximab at 1 μg/ml.21 Following 35 cycles of challenge, the A431 cells treated with ADCC conditions displayed complete resistance to ADCC, slower proliferation in vitro and in vivo, reduced EGFR expression, and loss of NK cell conjugation.